IMMUNE NETWORK

The Korean Association of Immunobiologists (대한면역학회)
권호 표지

Application of Apoptogenic Pretreatment to Enhance Anti-tumor Immunity of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)-secreting CT26 Tumor Cells

  • Jun, Do-Youn (Institute of Genetic Engineering, Kyungpook National University) ;
  • Jaffee, Elizabeth M (Division of Immunology and Hematopoiesis, The Sidney Kimmel Comprehensive Center at Johns Hopkins) ;
  • Kim, Young-Ho (Laboratory of Immunobiology, Department of Microbiology, College of Natural Sciences, Kyungpook National University)
  • Published : 2005.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: As an attempt to develop a strategy to improve the protective immune response to GM-CSF-secreting CT26 (GM-CSF/CT26) tumor vaccine, we have investigated whether the apoptogenic treatment of GM-CSF/CT26 prior to vaccination enhances the induction of anti-tumor immune response in mouse model. Methods: A carcinogeninduced mouse colorectal tumor, CT26 was transfected with GM-CSF gene using a retroviral vector to generate GM-CSF-secreting CT26 (CT26/GM-CSF). The CT26/GM-CSF was treated with ${\gamma}$-irradiation or mitomycin C to induce apoptosis and vaccinated into BALB/c mice. After 7 days, the mice were injected with a lethal dose of challenge live CT26 cells to examine the protective effect of tumor vaccination in vivo. Results: Although both apoptotic and necrotic CT26/GM-CSF vaccines were able to enhance anti-tumor immune response, apoptotic CT26/GM-CSF induced by pretreatment with ${\gamma}$-irradiation (50,000 rads) was the most potent in generating the anti-tumor immunity, and thus 100% of mice vaccinated with the apoptotic cells remained tumor free for more than 60 days after tumor challenge. Conclusion: Apoptogenic pretreatment of GM-CSF-secreting CT26 tumor vaccine by ${\gamma}$-irradiation (50,000 rads) resulted in a significant enhancement in inducing the protective anti-tumor immunity. A rapid induction of apoptosis of CT26/GM-CSF tumor vaccine at the vaccine site might be critical for the enhancement in anti-tumor immune response to tumor vaccine.

Keywords

References

  1. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E: Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172;1217-1224, 1990 https://doi.org/10.1084/jem.172.4.1217
  2. Dranoff G, Jaffee E, Lazenby A, Golumb P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Sci USA 90;3539-3543, 1993
  3. Simons JW, Jaffee EM, Weber CE, Levitsky HI, Nelson WG, Carducci MA, Lazenby AJ, Cohen LK, Finn CC, Clift SM, Hauda KM, Beck LA, Leiferman KM, Owens AH Jr, Piantadosi S, Dranof G, Mulligan RC, Pardoll DM, Marshall FF: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colonystimulating factor gene transfer. Cancer Res 57;1537-1546, 1997
  4. Soiffer R, Lynch TM, Jung K, Rhuda C, Schmollinger JC, Hodi FS, Liebster L, Lam P, Mentzer S, Singer S, Tanabe KK, Cosimi AB, Duda R, Sober A, Bhan A, Daley J, Neuberg D, Parry G, Rokovich J, Richards L, Drayer J, Berns A, Clift S, Cohen LK, Mulligan RC, Dranoff G: Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colonystimulating factor generates potent antitumor immunity in patient with meastatic melanoma. Proc Natl Acad Sci USA 95;13141-13146, 1998
  5. Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter B, Piantadosi S, Marshall FF, Nelson WG: Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 59;5160-5168, 1999
  6. Jaffee EM, Hruban RW, Biedrzycki B, Laheru D, Schepers K, Sauther PR, Goemann M, Coleman J, Grochow L, Donehower RC, Lillemoe KD, D'Reilly S, Abrams RA, Pardoll DM, Cameron JL, Yeo CJ: Novel allogenic granulocytemacrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase 1 trial of safety and immune activation. J Clin Oncol 19;145-156, 2001 https://doi.org/10.1200/JCO.2001.19.1.145
  7. Emens LA, Armstrong D, Biedrzycki B, Davidson N, Davis- Sproul J, Fetting J, Jaffee E, Onners B, Piantadosi S, Reilly RT, Stearns V, Tartakovsky I, Visvanathan K, Wolff A: A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin. Hum Gene Ther 15;313-337, 2004 https://doi.org/10.1089/104303404322886165
  8. Smith CA, Kingston R, Jenkinson EJ, Owen JJ, Williams GT: Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures. Nature 337;181-184, 1989 https://doi.org/10.1038/337181a0
  9. Wallach D, Boldin M, Varfolomeev E, Beyaert R, Vandenabeele P, Fiers W: Cell death induction by receptors of the TNF family: towards a molecular understanding. FEBS Lett 410;96-106, 1997 https://doi.org/10.1016/S0014-5793(97)00553-X
  10. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH: Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373;438-441, 1995 https://doi.org/10.1038/373438a0
  11. Buttke TM, Sandstrom PA: Oxidative stress as a mediator of apoptosis. Immunol Today 15;7-10, 1994 https://doi.org/10.1016/0167-5699(94)90018-3
  12. Kummer JL, Rao PK, Heidenreich KA: Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogenactivated protein kinase. J Biol Chem 272;20490-20494, 1997 https://doi.org/10.1074/jbc.272.33.20490
  13. Migliorati G, Nicoletti I, Crocicchio F, Pagliacci C, D'adamio F, Riccardi C: Heat shock induces apoptosis in mouse thymocytes and protects them from glucocorticoid-induced cell death. Cell Immunol 143;348-356, 1992 https://doi.org/10.1016/0008-8749(92)90031-J
  14. Rieber MS, Rieber M: UV radiation induces DNA fragmentation and cell death in B16 melanoma sensitized by bromodeoxyuridine: impaired c-jun induction and defective tyrosine phosphorylation signalling. Biochem Biophys Res Commun 203;1629-1637, 1994 https://doi.org/10.1006/bbrc.1994.2373
  15. Hannun YA: Apoptosis and dilemma of cancer chemotherapy. Blood 89;1845-1853, 1997
  16. Steinman RM, Turley S, Mellman I, Inaba K: The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 191;411-416, 2000 https://doi.org/10.1084/jem.191.3.411
  17. Rovere P, Vallinoto C, Bondanza A, Crosti MC, Rescigno M, Ricciardi-Castagnoli P, Rugarli C, Manfredi AA: Bystander apoptosis triggers dentritic cell maturation and antigen-presenting function. J Immunol 161;4467-4471, 1998
  18. Scheffer SR, Nave H, Korangy F, Schlote K, Pabst R, Jaffee EM, Manns MP, Greten TF: Apoptotic, but not necrotic, tumor cells vaccines induce a potent immune response in vivo. Int J Cancer 103;205-211, 2003 https://doi.org/10.1002/ijc.10777
  19. Bae MA, Kang HS, Rue SW, Seu JH, Kim YH: Enhanced expression of Fas ligand is associated with aburatubolactam C-induced apoptosis in human Jurkat T cells. Biochem Biophys Res Commun 246;276-281, 1998 https://doi.org/10.1006/bbrc.1998.8598
  20. Greten TF, Jaffee EM: Cancer vaccine. J Clinical Oncol 17;1047-1060, 1999 https://doi.org/10.1200/JCO.1999.17.3.1047
  21. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N: Consequences of cell death. Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 191;423-434, 2000 https://doi.org/10.1084/jem.191.3.423
  22. Boon T, Coulie DG, Van den Eynde B: Tumor antigens recognized by T cells. Immunol Today 18;267-268, 1997
  23. Chen YT: Cancer vaccine: identification of human tumor antigen by SEREX. Cancer J 6:208-217, 2000
  24. Henry F, Boisteau O, Bretaudeau L, Lieubeau B, Meflah K, Gegoire M: Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res 59;3329-3332, 1999
  25. Cao X, Zhang W, Wang J, Zhang M, Huang X, Hamada H, Chen W: Therapy of established tumor with a hybrid cellular vaccine generated by using granulocyte-macrophage colonystimulating factor genetically modified dendritic cells. Immunol 97;616-625, 1999 https://doi.org/10.1046/j.1365-2567.1999.00823.x
  26. Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FMJ: Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 35;2434-2439, 1984